[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360; 381-400; 401-420; 421-440; 441-460


NICE TAs 361-380






DHFT Formulary link


East Midlands Cancer Network link (cancer drugs only)

TA 361

Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal)              

Appraisal terminated               

TA 362

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small cell lung cancer (terminated appraisal)       


Appraisal terminated    

TA 363

Ledipasvir-sofosbuvir for treating chronic hepatitis C 

5.3 Antiviral drugs

TA 364

Daclatasvir for treating chronic hepatitis C

5.3 Antiviral drugs 

TA 365

Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C

5.3 Antiviral drugs 


TA 366

Pembrolizumab for advanced melanoma not previously treated with ipilimumab


EMCN guidelines


TA 367

Vortioxetine for treating major depressive episodes

Third-line use only by MH consultants (RED drug) 

TA 368

Apremilast for treating moderate to severe plaque psoriasis          

 Not recommended

TA 369

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears


11.4 Corticosteroids and other anti-inflammatory preparations  

TA 370

Bortezomib for previously untreated mantle cell lymphoma


TA 371

Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane.


 Not recommended
TA 372

Apremilast for treating active psoriatic arthritis.

 Not recommended

TA 373

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis                    

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout

TA 374

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy


EMCN guidelines


TA 375

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed 

10.1.2 - 10.1.4 Corticosteroids, rheumatic disease suppressants, gout


TA 376

Radium‑223 dichloride is recommended as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if:
  • they have had treatment with docetaxel, and
the company provides radium‑223 dichloride with the discount agreed in the patient access scheme


EMCN guidelines

TA 377

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated


EMCN guidelines


TA 378

Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy

Not recommended


TA 379

Nintedanib for treating idiopathic pulmonary fibrosis 

To be initiated only via tertiary specialist after respiratory MDT review


TA 380

Panobinostat for treating multiple myeloma after at least 2 previous treatments